NCT06218654 Hemodynamic Instability of Patient With Spontaneous Subarachnoid Hemorrhage
| NCT ID | NCT06218654 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Condition | Subarachnoid Hemorrhage, Spontaneous |
| Study Type | OBSERVATIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-01-15 |
| Primary Completion | 2025-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 90 participants in total. It began in 2024-01-15 with a primary completion date of 2025-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the role of biomarkers in spontaneous subarachnoid hemorrhage (sSAH) as predictors of severity of clinical outcome. The test of biomarkers is based on regular blood and urinary samples. Blood levels of highly specific cardiac troponin (cTNI), natriuretic peptides (NT-ProBNP), S100 beta protein, neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase (UCH-L1), soluble Tumor Necrosis Factor Receptor-2 (sST2), and soluble urokinase plasminogen activator receptor (suPAR), as well as urinary levels of epinephrine and norepinephrine are the biomarkers explored. All adult participants with spontaneous subarachnoid hemorrhage are involved in the study. The main questions aim to answer are: * which of these molecules can be prognostic for patients' outcome * which are the prognostic levels of these biomarkers to predict patients' outcome. Participants will undergo blood and urinary samples during hospitalization at 24 hours, 72 hours and after 7 days.
Eligibility Criteria
Inclusion Criteria: * Patients with spontaneous subarachnoid hemorrhage, including those with perimesencephalic subarachnoid hemorrhage and aneurysmal subarachnoid hemorrhage. * Adult patients. * Confirmed presence of spontaneous subarachnoid hemorrhage through neuroimaging. * Obtained informed consent for specific study biomarkers Exclusion Criteria: * Age \<18 years. * Post-traumatic subarachnoid hemorrhage.
Contact & Investigator
Giuseppe Maria Della Pepa
PRINCIPAL INVESTIGATOR
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Frequently Asked Questions
Who can join the NCT06218654 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Subarachnoid Hemorrhage, Spontaneous. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06218654 currently recruiting?
Yes, NCT06218654 is actively recruiting participants. Contact the research team at giuseppemaria.dellapepa@policlinicogemelli.it for enrollment information.
Where is the NCT06218654 trial being conducted?
This trial is being conducted at Roma, Italy.
Who is sponsoring the NCT06218654 clinical trial?
NCT06218654 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The principal investigator is Giuseppe Maria Della Pepa at Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The trial plans to enroll 90 participants.